- Home
- SBRA vs LNTH Comparison
SBRA vs LNTH Comparison
Compare SBRA & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBRA | LNTH |
|---|---|---|
| Founded | 2010 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.9B |
| IPO Year | 2010 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SBRA | LNTH |
|---|---|---|
| Price | $19.75 | $75.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $21.88 | ★ $83.20 |
| AVG Volume (30 Days) | ★ 2.1M | 1.1M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.13% | N/A |
| EPS Growth | ★ 18.52 | N/A |
| EPS | 0.64 | ★ 3.41 |
| Revenue | ★ $774,632,000.00 | $343,374,000.00 |
| Revenue This Year | $7.50 | N/A |
| Revenue Next Year | $9.07 | $13.47 |
| P/E Ratio | $30.59 | ★ $22.42 |
| Revenue Growth | ★ 10.15 | 3.62 |
| 52 Week Low | $15.75 | $47.27 |
| 52 Week High | $21.07 | $108.86 |
Technical Indicators
Market Signals| Indicator | SBRA | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 50.52 |
| Support Level | $18.16 | $70.73 |
| Resistance Level | $20.94 | $83.70 |
| Average True Range (ATR) | 0.45 | 3.14 |
| MACD | -0.15 | -0.68 |
| Stochastic Oscillator | 16.30 | 32.86 |
Price Performance
Historical ComparisonAbout SBRA Sabra Health Care REIT Inc.
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.